



DMPK BIOANALYSIS

CAPABILITIES



SMALL MOLECULES

- Mass spectrometry-based analysis
- Parent and metabolites from PK, PK/PD, in vitro ADME, metabolite identification
- Matrices: biological fluids and tissues

LARGE MOLECULES

- ELISA and MSD and mass spectrometry-based analysis
 - PK, PK/PD, biomarker test and immunogenicity test
 - Bioassay

METABOLOMICS AND BIOMARKER ANALYSIS CASE STUDIES



BIOMARKER ANALYSIS

- A set of cell pellets produced with known numbers of cells
- Extracts made and analyzed by LCMS/MS
- Resulting acetyl CoA in extract plotted against numbers of the cells loaded
- LC-MS/MS signal responses correlated with cell numbers
- Optimized cell numbers, washing factor evaluated and cell handling time optimized

REGULATED BIOANALYSIS

ASSAY METHOD FOR DOXORUBICIN QUANTIFICATION

- Objective
 - Due to in vivo PK difference, separation of free and encapsulated drug in plasma is needed
- Challenge
 - Liposome is fragile
 - Heat exposure, non-isotonic condition and thawing can produce premature bursting of the liposome
 - Sample preparation
- SPE Procedures
 - SPE plate selection
 - SPE procedure optimization
- LC-MS/MS Conditions
 - Column: Waters Xbridge C18 (2.1X50 mm, 3.5 um)
 - Mobile phase: Water: Acetonitrile: Formic Acid (10:90:0.2, v/v/v)
 - API 6500, TIS, positive

| QUALIFICATION ELEMENT | | | RESULTS | CRITERIA |
|-----------------------|-------------------------|---------------------|-----------------|---|
| Accuracy | Calibration Curve (n=6) | 20.0~2000pg/ml | -2.8%~3.2% | Accuracy within $\pm 15.0\%$, except LLOQ within $\pm 20.0\%$ |
| Accuracy | Intra-assay (n=6) | LLOQ QC | 5.2% | Within $\pm 15.0\%$, except at the LLOQ where it should be within $\pm 20.0\%$ |
| | | Low QC | 1.8% | |
| | | Medium QC | 2.5% | |
| | | High QC | -2.5% | |
| | Inter-assay (n=18) | LLOQ QC | 2.7% | Within $\pm 15.0\%$, except at the LLOQ where it should be within $\pm 20.0\%$ |
| | | Low QC | 2.0% | |
| Medium QC | | 2.7% | | |
| Precision | Intra-assay (n=6) | LLOQ QC | 8.4% | $\leq 15.0\%$ except at the LLOQ where it should not exceed 20.0% |
| | | Low QC | 3.4% | |
| | | Medium QC | 2.8% | |
| | | High QC | 3.0% | |
| | Inter-assay (n=18) | LLOQ QC | 8.1% | $\leq 15.0\%$ except at the LLOQ where it should not exceed 20.0% |
| | | Low QC | 3.2% | |
| | | Medium QC | 2.8% | |
| | | High QC | 3.9% | |
| Selectivity | Plasma (n=6) | | No interference | $< 20.0\%$ of the mean response of the accepted LLOQ |
| Dilution Integrity | Dilution Factor: 20 | Accuracy | 5.8% | Within $\pm 15.0\%$ |
| | | Precision | 2.4% | $\leq 15.0\%$ |
| Robustness | Plasma Stability | RT (8 hr) | -6.5%~1.8% | Accuracy within $\pm 15.0\%$ for 2/3 samples |
| | | LT (-70oC, 30 days) | -6.4%~6.1% | |
| | | FT (4 cycles) | -7.5%~-1.1% | |
| Extraction Recovery | Recovery | Blood Stability | 48 min | Ratio difference between Tn and T0 within $\pm 15.0\%$ |
| | | Low QC | 86.3% | $\%CV \leq 20.0\%$ |
| | | Medium QC | 83.3% | |
| | High QC | 88.7% | | |
| Precision (CV%) | | 3.1%~5.6% | | |
| Matrix Effect | IS-normalized MF | Low QC | 3.6% | IS-normalized MF $< 15.0\%$ |
| | | High QC | 2.2% | |

LEARN MORE AT [CHEMPARTNER.COM/SERVICES/DMPK-EXPLORATORY-TOXICOLOGY/BIOANALYSIS/](https://chempartner.com/services/dmpk-exploratory-toxicology/bioanalysis/)